Fall Outlook: Cannabis Stock Forecast

Sector Drivers & Market Expectations

Heading into the final quarters of the year, market sentiment seems to be defined by three core dynamics:

• Tax Relief Realization: The federal transition of medical cannabis to Schedule III remains a primary focus for U.S. operators. The anticipated relief from Section 280E tax liabilities is projected to improve operational liquidity, potentially allowing MSOs to redirect capital toward debt reduction or reinvestment rather than cash preservation. 
• Big Investors and Stock Exchanges: Major stock exchanges like the NYSE and NASDAQ still do not allow U.S. cannabis companies to list their shares directly because the plant remains federally illegal. This keeps many large investment funds on the sidelines. Until Congress passes federal banking reform or the exchanges change their rules, big institutional money will have a hard time flowing directly into American cannabis stocks. 
• Mergers and Buying Out Competitors: Because stock values across the industry are low, big cannabis operators are acquiring smaller brands by trading shares rather than taking on expensive loans. Their main goal remains building dominance and expanding footprint in high-volume states like Florida, Illinois, and Nevada. 

Financial Performance of Major MSOs 

Recent Q2 earnings reports highlight distinct operational strategies among major MSOs adjusting to ongoing price compression:

Green Thumb Industries (GTI)

• Q2 Performance: Reported $306.7 million in revenue (up 4.6% YoY) and $84.3 million in normalized EBITDA (27.5% margin). Gross margins stood at 45%, reflecting continued price discounting across retail channels.
• Balance Sheet: Maintained $283.6 million in cash reserves and low leverage relative to sector peers, continuing to allocate capital toward strategic share buybacks alongside organic operations.

Curaleaf Holdings

• Q2 Performance: Posted $340 million in revenue (up 10% YoY), supported by a 7% increase in domestic revenue and a 26% gain in international sales. Adjusted EBITDA reached $70 million (20.6% margin) with a 50% gross margin.
• Balance Sheet: Ended the quarter with $107 million in cash. Curaleaf continues to expand its European operational footprint to offset domestic market price compression while maintaining a retail network of 176 dispensaries.

Trulieve Cannabis Corp.

• Q2 Performance: Generated $271 million in revenue with a 60% gross margin. Adjusted EBITDA reached $97.5 million (36% margin), yielding $53 million in operating cash flow.
• Balance Sheet: Holds $325 million in cash against $289 million in total debt. This position provides capital flexibility as the operator prepares for possible adult-use market expansion in Florida.

Key Risks & Autumn Catalysts

While stocks may look cheap right now, companies still have to navigate a few key hurdles this fall: 

• Administrative Timelines: Extended regulatory and administrative processes surrounding federal rescheduling could delay capital inflows.
• Price Deflation: Ongoing wholesale price compression in mature state markets continues to weigh on gross margins, requiring higher sales volumes to maintain top-line revenue levels.
• Earnings Benchmarks: Q3 financial results will indicate whether ongoing corporate cost reductions are sufficient to protect free cash flow through year-end.

Final Thoughts

At the end of the day, while falling prices and federal delays continue to test everyone’s patience, there is reason for cautious optimism. Upcoming policy changes, especially potential tax relief from Schedule III and new state market expansions, could finally give cannabis companies the boost they need to stabilize their stock values by the end of the year. Investors should keep a close eye on third-quarter cash flow reports to see which brands are best positioned to ride the next wave.

Read more from Soft Secrets:

• Vireo Growth Acquires Planet 13 in Strategic All-Stock Merger

• How Patent Trolls Target Commercial Cannabis

• U.S. Cannabis Media Outlets Launch Green Press Collective

Disclaimer: This article is provided for informational and educational purposes only and does not constitute legal, financial, or professional advice.